PAYS — PaySign, Inc.

Summary of Paysign Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Increased 40.5% year-over-year to $82 million for 2025.
• Net Income: Rose 98% to $7.6 million.
• Adjusted EBITDA: Increased 107% to $19.9 million.
• Operating Margins: Improved significantly by 723 basis points to 9%, indicating enhanced operational efficiency.
• Patient Affordability Revenue: Grew 168% to $33.9 million, with processed claims up 79%.
• Plasma Compensation Revenue: Increased 4% to $45.6 million, driven by a net addition of 115 centers, totaling 595 centers by year-end.
• Cash Position: Exited 2025 with $21.1 million in cash, nearly double from the previous year.

2. Strategic Updates and Business Highlights

• The patient affordability platform has become a central growth driver, delivering nearly $1 billion in financial assistance to patients in 2025.
• The company added 55 new patient affordability programs, bringing the total to 131 across over 70 clients, including 6 of the top 10 U.S. pharmaceutical manufacturers.
• The dynamic business rules technology saved clients over $325 million in 2025, enhancing the platform's value proposition.
• The plasma donor compensation business is expected to grow primarily through increased center capacity rather than new openings.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $106.5 million and $110.5 million, reflecting 30% to 35% year-over-year growth.
• Gross Profit Margins: Projected to be between 60% and 62%.
• Operating Expenses: Anticipated to increase by 20% due to investments in personnel and technology.
• Net Income: Expected to nearly double to a range of $13 million to $16 million.
• First Quarter 2026 Revenue: Projected at $27 million to $27.5 million, representing a growth of 45.2% to 47.8% compared to Q1 2025.

4. Bad News, Challenges, or Points of Concern

• Although the plasma business is stable, average plasma donations per center declined due to elevated inventory levels, impacting revenue per center.
• The company faces competitive pressures from emerging players in the patient affordability space, although management believes their innovative solutions provide a strong competitive edge.
• Concerns were raised regarding the understanding of co-pay programs among investors, which may affect stock performance despite solid fundamentals.

5. Notable Q&A Insights

• Management emphasized that there is no slowdown in activity from pharmaceutical manufacturers, countering industry speculation.
• The company does not view the expansion of direct-to-consumer models or pharmacy discount programs as significant threats to their core business, which focuses on high-cost branded therapies.
• The dynamic business rules technology is seen as a competitive advantage, and management is exploring AI to enhance their offerings further.
• There is optimism about the growth potential in the patient affordability segment, with management suggesting they are in the early stages of market penetration and growth.

Overall, Paysign Inc. reported strong financial performance in 2025, with significant growth in its patient affordability business and a stable plasma compensation segment. The outlook for 2026 remains positive, though the company is aware of competitive pressures and market dynamics that could impact future performance.